159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

Emiel De Jaeghere; Sandra Tuyaerts; An Van Nuffel; Lien Lippens; An Hendrix; Peter Vuylsteke; xuan bich trinh; Peter A Van Dam; Sandrine Aspeslagh; Alex De Caluwé; Eline Naert; Koen Van de Vijver; Frederic Amant; Katrien Vandecasteele; Hannelore Denys

doi:10.1016/j.annonc.2021.10.178

159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

Emiel De Jaeghere, Sandra Tuyaerts, An Van Nuffel, Lien Lippens, An Hendrix, Peter Vuylsteke, xuan bich trinh, Peter A Van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore Denys

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1449-1450
Number of pages	2
Journal	Annals of Oncology
Volume	32
Issue number	suppl 7
DOIs	https://doi.org/10.1016/j.annonc.2021.10.178
Publication status	Published - Dec 2021

Access to Document

10.1016/j.annonc.2021.10.178Licence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

De Jaeghere, E., Tuyaerts, S., Van Nuffel, A., Lippens, L., Hendrix, A., Vuylsteke, P., trinh, X. B., Van Dam, P. A., Aspeslagh, S., De Caluwé, A., Naert, E., Van de Vijver, K., Amant, F., Vandecasteele, K., & Denys, H. (2021). 159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma. Annals of Oncology, 32(suppl 7), 1449-1450. https://doi.org/10.1016/j.annonc.2021.10.178

@article{26bee6812e634911a84ad5cf35a40f4b,

title = "159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma",

author = "{De Jaeghere}, Emiel and Sandra Tuyaerts and {Van Nuffel}, An and Lien Lippens and An Hendrix and Peter Vuylsteke and trinh, {xuan bich} and {Van Dam}, {Peter A} and Sandrine Aspeslagh and {De Caluw{\'e}}, Alex and Eline Naert and {Van de Vijver}, Koen and Frederic Amant and Katrien Vandecasteele and Hannelore Denys",

year = "2021",

month = dec,

doi = "10.1016/j.annonc.2021.10.178",

language = "English",

volume = "32",

pages = "1449--1450",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "suppl 7",

}

De Jaeghere, E, Tuyaerts, S, Van Nuffel, A, Lippens, L, Hendrix, A, Vuylsteke, P, trinh, XB, Van Dam, PA, Aspeslagh, S, De Caluwé, A, Naert, E, Van de Vijver, K, Amant, F, Vandecasteele, K & Denys, H 2021, '159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma', Annals of Oncology, vol. 32, no. suppl 7, pp. 1449-1450. https://doi.org/10.1016/j.annonc.2021.10.178

TY - JOUR

T1 - 159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

AU - De Jaeghere, Emiel

AU - Tuyaerts, Sandra

AU - Van Nuffel, An

AU - Lippens, Lien

AU - Hendrix, An

AU - Vuylsteke, Peter

AU - trinh, xuan bich

AU - Van Dam, Peter A

AU - Aspeslagh, Sandrine

AU - De Caluwé, Alex

AU - Naert, Eline

AU - Van de Vijver, Koen

AU - Amant, Frederic

AU - Vandecasteele, Katrien

AU - Denys, Hannelore

PY - 2021/12

Y1 - 2021/12

UR - http://dx.doi.org/10.1016/j.annonc.2021.10.178

U2 - 10.1016/j.annonc.2021.10.178

DO - 10.1016/j.annonc.2021.10.178

M3 - Article

SN - 0923-7534

VL - 32

SP - 1449

EP - 1450

JO - Annals of Oncology

JF - Annals of Oncology

IS - suppl 7

ER -

159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

Access to Document

Handle.net

Other files and links

Cite this